- Home
- ICON vs ENVB Comparison
ICON vs ENVB Comparison
Compare ICON & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- ENVB
- Stock Information
- Founded
- ICON 2023
- ENVB 1994
- Country
- ICON Greece
- ENVB United States
- Employees
- ICON N/A
- ENVB N/A
- Industry
- ICON
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- ENVB Health Care
- Exchange
- ICON Nasdaq
- ENVB Nasdaq
- Market Cap
- ICON 3.6M
- ENVB 3.2M
- IPO Year
- ICON 2024
- ENVB N/A
- Fundamental
- Price
- ICON $1.68
- ENVB $1.30
- Analyst Decision
- ICON Strong Buy
- ENVB Strong Buy
- Analyst Count
- ICON 1
- ENVB 1
- Target Price
- ICON $4.50
- ENVB $10.00
- AVG Volume (30 Days)
- ICON 62.0K
- ENVB 461.6K
- Earning Date
- ICON 06-17-2025
- ENVB 05-14-2025
- Dividend Yield
- ICON 206.67%
- ENVB N/A
- EPS Growth
- ICON N/A
- ENVB N/A
- EPS
- ICON N/A
- ENVB N/A
- Revenue
- ICON $5,309,000.00
- ENVB N/A
- Revenue This Year
- ICON $76.76
- ENVB N/A
- Revenue Next Year
- ICON $30.43
- ENVB N/A
- P/E Ratio
- ICON N/A
- ENVB N/A
- Revenue Growth
- ICON 18.61
- ENVB N/A
- 52 Week Low
- ICON $1.60
- ENVB $1.01
- 52 Week High
- ICON $154.00
- ENVB $11.82
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- ENVB 45.17
- Support Level
- ICON N/A
- ENVB $1.11
- Resistance Level
- ICON N/A
- ENVB $1.34
- Average True Range (ATR)
- ICON 0.00
- ENVB 0.10
- MACD
- ICON 0.00
- ENVB 0.04
- Stochastic Oscillator
- ICON 0.00
- ENVB 70.26
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.